Harnessing invariant NKT cells in vaccination strategies

Nature Reviews Immunology

Volumn 9, Issue 1, 2009, Pages 28-38

  Cerundolo, Vincenzo ^a   Silk, Jonathan D ^a   Masri, S Hajar ^a   Salio, Mariolina ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ALPHA GLUCURONOSYLCERAMIDE; ANTIGEN; CYTOKINE; DENDRITIC CELL VACCINE; GLYCOLIPID; GLYCOLIPID II; IMMUNOLOGICAL ADJUVANT; INVARIANT NATURAL KILLER T CELL AGONIST; ISOGLOBOTRIHEXOSYLCERAMIDE; PHOSPHATIDYLINOSITOL TETRAMANNOSIDE; T LYMPHOCYTE RECEPTOR; TYHREITOLCERAMIDE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL INTERACTION; CELL MATURATION; CELLULAR IMMUNITY; CHEMICAL MODIFICATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DOSE ESCALATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INVARIANT NATURAL KILLER T CELL; LUNG NON SMALL CELL CANCER; LYMPHOCYTE ACTIVATION; MYELOMA; NATURAL KILLER T CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD1D; B-LYMPHOCYTES; CELL DIFFERENTIATION; CLINICAL TRIALS AS TOPIC; CYTOKINES; DENDRITIC CELLS; FORECASTING; GALACTOSYLCERAMIDES; GLYCOLIPIDS; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC SURVEILLANCE; INFECTION; LYMPHOCYTE ACTIVATION; MICE; MODELS, MOLECULAR; NATURAL KILLER T-CELLS; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; STRUCTURE-ACTIVITY RELATIONSHIP; VACCINATION;

EID: 58149104377     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2451     Document Type: Review

References (127)

1. Donnelly, J. J., Wahren, B. & Liu, M. A. DNA vaccines: progress and challenges. J. Immunol. 175, 633-639 (2005).
2. Hanke, T., Goonetilleke, N., McMichael, A. J. & Dorrell, L. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J. Gen. Virol. 88, 1-12 (2007).
3. Smith, C. L et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int. J. Cancer 113, 259-266 (2005).
4. Godfrey, D. I. & Berzins, S. P. Control points in NKT-cell development. Nature Rev. Immunol. 7, 505-518 (2007).
5. Matsuda, J. L., Mallevaey, T., Scott-Browne, J. & Gapin, L. CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system. Curr. Opin. Immunol. 20, 358-368 (2008).
6. Kinjo, Y. et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nature Immunol. 7, 978-986 (2006).
7. Kinjo, Y. et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434, 520-525 (2005).
8. Mattner, J. et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434, 525-529 (2005).
9. Mattner, J. et al. Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe 3, 304-315 (2008).
10. Sriram, V., Du, W., Gervay-Hague, J. & Brutkiewicz, R. R. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur. J. Immunol. 35, 1692-1701 (2005). References 6-8 and 10 show for the first time that most iNKT cells are activated by glycosphingolipid and diacylglycerol of bacterial origin.
11. Kinjo, Y. et al. Natural sphingomonas glycolipids vary greatly in their ability to activate natural killer T cells. Chem. Biol. 15, 654-664 (2008).
12. Amprey, J. L. et al. A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J. Exp. Med. 200, 895-904 (2004).
13. Fischer, K. et al. Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc. Natl Acad. Sci. USA 101, 10685-10690 (2004).
14. Brigl, M., Bry, L., Kent, S. C., Gumperz, J. E. & Brenner, M. B. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nature Immunol. 4, 1230-1237 (2003).
15. Paget, C. et al. Activation of invariant NKT cells by Toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. Immunity 27, 597-609 (2007).
16. Salio, M. et al. Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation. Proc. Natl Acad. Sci. USA 104, 20490-20495 (2007).
17. Nagarajan, N. A. & Kronenberg, M. Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J. Immunol. 178, 2706-2713 (2007). References 14-17 describe the different modes of activation of iNKT cells: direct (refs 15, 16), indirect (ref. 14) and CD1d independent (ref. 17).
18. Kawano, T. et al. CD1d-restricted and TCR-mediated activation of vα14 NKT cells by glycosylceramides. Science 278, 1626-1629 (1997).
19. Morita, M. et al. Structure-activity relationship of α-galactosylceramides against B16-bearing mice. J. Med. Chem. 38, 2176-2187 (1995).
20. Savage, P. B., Teyton, L. & Bendelac, A. Glycolipids for natural killer T cells. Chem. Soc. Rev. 35, 771-779 (2006).
21. Kim, S. et al. Impact of bacteria on the phenotype, functions, and therapeutic activities of invariant NKT cells in mice. J. Clin. Invest. 118, 2301-2315 (2008).
22. Parekh, V. V. et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J. Clin. Invest. 115, 2572-2583 (2005).
23. Uldrich, A. P. et al. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J. Immunol. 175, 3092-3101 (2005).
24. McCarthy, C. et al. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J. Exp. Med. 204, 1131-1144 (2007).
25. Silk, J. et al. Non-glycosidic CD1d lipid ligands activate human and murine invariant NKT cells. J. Immunol. 180, 6452-6456 (2008).
26. Smyth, M. J. et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191, 661-668 (2000).
27. Crowe, N. Y., Smyth, M. J. & Godfrey, D. I. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196, 119-127 (2002).
28. Carnaud, C. et al. Cutting Edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163, 4647-4650 (1999).
29. Hayakawa, Y. et al. IFN-γ-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, α-galactosylceramide. Blood 100, 1728-1733 (2002).
30. De Santo, C. et al. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J. Clin. Invest. 13 Nov 2008 (doi: 10.1172/JCI36264). This work highlights a new role for iNKT cells that is based on their ability to relieve the suppressive activity of MDSCs.
31. Renukaradhya, G. J. et al. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood 111, 5637-5645 (2008).
32. Spada, F. M., Koezuka, Y. & Porcelli, S. A. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J. Exp. Med. 188, 1529-1534 (1998).
33. Vincent, M. S. et al. CD1-dependent dendritic cell instruction. Nature Immunol. 3, 1163-1168 (2002).
34. Fujii, S., Liu, K., Smith, C., Bonito, A. J. & Steinman, R. M. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J. Exp. Med. 199, 1607-1618 (2004).
35. + T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J. Immunol. 171, 5140-5147 (2003).
36. Gonzalez-Aseguinolaza, G. et al. Natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195, 617-624 (2002).
37. Fujii, S., Shimizu, K., Smith, C., Bonifaz, L. & Steinman, R. M. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198, 267-279 (2003). References 35-37 show that co-injection of α-GalCer with antigenic proteins increases antigen-specific B- and T-cell responses.
38. Silk, J. D. et al. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J. Clin. Invest. 114, 1800-1811 (2004).
39. + T cells in vivo. J. Immunol. 170, 2540-2548 (2003).
40. + cytotoxic T cell responses by inducing CD70 expression on dendritic cells. J. Immunol. 180, 4615-4620 (2008).
41. + Th cell antitumor immunity in mice. J. Clin. Invest. 117, 3330-3338 (2007).
42. Hermans, I. F. et al. Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells. J. Immunol. 178, 2721-2729 (2007).
43. Reis e Sousa, C. Dendritic cells in a mature age. Nature Rev. Immunol. 6, 476-483 (2006).
44. Galli, G. et al. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J. Exp. Med. 197, 1051-1057 (2003).
45. Galli, G. et al. Invariant NKT cells sustain specific B cell responses and memory. Proc. Natl Acad. Sci. USA 104, 3984-3989 (2007).
46. Barral, P. et al. B cell receptor-mediated uptake of CD1d-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo. Proc. Natl Acad. Sci. USA 105, 8345-8350 (2008).
47. Leadbetter, E. A. et al. NK T cells provide lipid antigen-specific cognate help for B cells. Proc. Natl Acad. Sci. USA 105, 8339-8344 (2008). References 45-47 describe the ability of iNKT cells to directly provide help to B cells. References 46 and 47 describe two new protocols to promote antibody responses in vivo by recruiting iNKT cells.
48. Fujii, S., Shimizu, K., Kronenberg, M. & Steinman, R. M. Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide- loaded DCs. Nature Immunol. 3, 867-874 (2002).
49. Schmieg, J., Yang, G., Franck, R. W., Van Rooijen, N. & Tsuji, M. Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc. Natl Acad. Sci. USA 102, 1127-1132 (2005).
50. Ko, S. Y. et al. α-galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J. Immunol. 175, 3309-3317 (2005).
51. Kamijuku, H. et al. Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses. Mucosal Immunol. 1, 208-218 (2008).
52. Chung, Y., Chang, W. S., Kim, S. & Kang, C. Y. NKT cell ligand α-galactosylceramide blocks the induction of oral tolerance by triggering dendritic cell maturation. Eur. J. Immunol. 34, 2471-2479 (2004).
53. Huang, Y. et al. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, α-galactosylceramide. Vaccine 26, 1807-1816 (2008).
54. Gabrilovich, D. I. et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67, 425 (2007).
55. Crowe, N. Y. et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J. Immunol. 171, 4020-4027 (2003).
56. Wilson, M. T. et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc. Natl Acad. Sci. USA 100, 10913-10918 (2003).
57. Harada, M. et al. Down-regulation of the invariant Vα14 antigen receptor in NKT cells upon activation. Int. Immunol. 16, 241-247 (2004).
58. Coquet, J. M. et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1-NKT cell population. Proc. Natl Acad. Sci. USA 105, 11287-11292 (2008).
59. H2 bias of natural killer T cells. Nature 413, 531-534 (2001).
60. Chang, Y. J. et al. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc. Natl Acad. Sci. USA 104, 10299-10304 (2007).
61. Schmieg, J., Yang, G., Franck, R. W. & Tsuji, M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-galactosylceramide. J. Exp. Med. 198, 1631-1641 (2003).
62. Bezbradica, J. S. et al. Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J. Immunol. 174, 4696-4705 (2005).
63. Yu, K. O. et al. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of α-galactosylceramides. Proc. Natl Acad. Sci. USA 102, 3383-3388 (2005).
64. Gadola, S. D. et al. Structure and binding kinetics of three different human CD1d-α-galactosylceramide-specific T cell receptors. J. Exp. Med. 203, 699-710 (2006).
65. Sidobre, S. et al. The T cell antigen receptor expressed by Vα14i NKT cells has a unique mode of glycosphingolipid antigen recognition. Proc. Natl Acad. Sci. USA 101, 12254-12259 (2004).
66. Chiba, A., Dascher, C. C., Besra, G. S. & Brenner, M. B. Rapid NKT cell responses are self-terminating during the course of microbial infection. J. Immunol. 181, 2292-2302 (2008).
67. Schwartz, R. H. T cell anergy. Annu. Rev. Immunol. 21, 305-334 (2003).
68. Ota, T. et al. IFN-γ-mediated negative feedback regulation of NKT-cell function by CD94/NKG2. Blood 106, 184-192 (2005).
69. Chang, D. H. et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201, 1503-1517 (2005).
70. Koch, M. et al. The crystal structure of human CD1d with and without α-galactosylceramide. Nature Immunol. 6, 819-826 (2005).
71. Zajonc, D. M. et al. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nature Immunol. 6, 810-818 (2005).
72. Borg, N. A. et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448, 44-49 (2007).
73. Godfrey, D. I., Rossjohn, J. & McCluskey, J. The fidelity, occasional promiscuity, and versatility of T cell receptor recognition. Immunity 28, 304-314 (2008).
74. Wu, D. et al. Design of natural killer T cell activators: structure and function of a microbial glycosphingolipid bound to mouse CD1d. Proc. Natl Acad. Sci. USA 103, 3972-3977 (2006).
75. Zajonc, D. M., Savage, P. B., Bendelac, A., Wilson, I. A. & Teyton, L. Crystal structures of mouse CD1d-iGb3 complex and its cognate Vα14 T cell receptor suggest a model for dual recognition of foreign and self glycolipids. J. Mol. Biol. 377, 1104-1116 (2008).
76. Scott-Browne, J. P. et al. Germline encoded recognition of diverse glycolipids by NKT cells. Nature Immunol. 8, 1105-1113 (2007).
77. Wun, K. S. et al. A minimal binding footprint on CD1d-glycolipid is a basis for selection of the unique human NKT TCR. J. Exp. Med. 205, 939-949 (2008). References 72, 76 and 77 describe the unique model of antigen recognition by the iNKT-cell TCR.
78. Brossay, L. et al. Structural requirements for galactosylceramide recognition by CD1-restricted NK T cells. J. Immunol. 161, 5124-5128 (1998).
79. Naidenko, O. V. et al. Binding and antigen presentation of ceramide-containing glycolipids by soluble mouse and human CD1d molecules. J. Exp. Med. 190, 1069-1080 (1999).
80. Oki, S., Chiba, A., Yamamura, T. & Miyake, S. The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J. Clin. Invest. 113, 1631-1640 (2004).
81. Goff, R. D. et al. Effects of lipid chain lengths in α-galactosylceramides on cytokine release by natural killer T cells. J. Am. Chem. Soc. 126, 13602-13603 (2004).
82. Stanic, A. K. et al. Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor. J. Immunol. 171, 4539-4551 (2003).
83. Denkberg, G. et al. Phage display-derived recombinant antibodies with TCR-like specificity against α-galactosylceramide and its analogues in complex with human CD1d molecules. Eur. J. Immunol. 38, 829-840 (2008).
84. Yu, K. O. et al. Production and characterization of monoclonal antibodies against complexes of the NKT cell ligand α-galactosylceramide bound to mouse CD1d. J. Immunol. Methods 323, 11-23 (2007).
85. Miyake, S. & Yamamura, T. NKT cells and autoimmune diseases: unraveling the complexity. Curr. Top. Microbiol. Immunol. 314, 251-267 (2007).
86. + T cells in a TH2 response and in immunoglobulin E production. Science 270, 1845-1847 (1995).
87. Fujii, S. et al. Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc. Natl Acad. Sci. USA 103, 11252-11257 (2006).
88. Ortaldo, J. R. et al. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J. Immunol. 172, 943-953 (2004).
89. Parekh, V. V. et al. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct α- and β-anomeric glycolipids. J. Immunol. 173, 3693-3706 (2004).
90. Van Kaer, L. α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nature Rev. Immunol. 5, 31-42 (2005).
91. Giaccone, G. et al. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8, 3702-3709 (2002).
92. + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103, 383-389 (2004).
93. Ishikawa, A. et al. A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 11, 1910-1917 (2005).
94. Uchida, T. et al. Phase I study of α-galactosylceramide- pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol. Immunother. 57, 337-345 (2008).
95. Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A. & Dudley, M. E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nature Rev. Cancer 8, 299-308 (2008).
96. Motohashi, S. et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 12, 6079-6086 (2006).
97. Stirnemann, K. et al. Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice. J. Clin. Invest. 118, 994-1005 (2008).
98. Godfrey, D. I., MacDonald, H. R., Kronenberg, M., Smyth, M. J. & Van Kaer, L. NKT cells: what's in a name? Nature Rev. Immunol. 4, 231-237 (2004).
99. Benlagha, K., Weiss, A., Beavis, A., Teyton, L. & Bendelac, A. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J. Exp. Med. 191, 1895-1903 (2000).
100. Karadimitris, A. et al. Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proc. Natl Acad. Sci. USA 98, 3294-3298 (2001).
101. Matsuda, J. L. et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192, 741-754 (2000).
102. Gumperz, J. E., Miyake, S., Yamamura, T. & Brenner, M. B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195, 625-636 (2002).
103. Lee, P. T., Benlagha, K., Teyton, L. & Bendelac, A. Distinct functional lineages of human Vα24 natural killer T cells. J. Exp. Med. 195, 637-641 (2002).
104. Liu, T. Y. et al. Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells. Eur. J. Immunol. 38, 1012-1023 (2008).
105. Crowe, N. Y. et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 202, 1279-1288 (2005).
106. McNab, F. W. et al. Peripheral NK1.1 NKT cells are mature and functionally distinct from their thymic counterparts. J. Immunol. 179, 6630-6637 (2007).
107. Rachitskaya, A. V. et al. Cutting Edge: NKT cells constitutively express IL-23 receptor and RORγt and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J. Immunol. 180, 5167-5171 (2008).
108. neg iNKT cell population involved in airway neutrophilia. J. Exp. Med. 204, 995-1001 (2007).
109. Yoshiga, Y. et al. Invariant NKT cells produce IL-17 through IL-23-dependent and -independent pathways with potential modulation of Th17 response in collagen-induced arthritis. Int. J. Mol. Med. 22, 369-374 (2008).
110. + NKT cell subsets with distinct cytokine-producing capacity. Blood 100, 11-16 (2002).
111. Thomas, S. Y. et al. CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J. Immunol. 171, 2571-2580 (2003).
112. Johnston, B., Kim, C. H., Soler, D., Emoto, M. & Butcher, E. C. Differential chemokine responses and homing patterns of murine TCR αβ NKT cell subsets. J. Immunol. 171, 2960-2969 (2003).
113. + NKT cells patrolling liver sinusoids. PLoS Biol. 3, e113 (2005).
114. Stanic, A. K. et al. Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by β-D-glucosylceramide synthase deficiency. Proc. Natl Acad. Sci. USA 100, 1849-1854 (2003).
115. Zhou, D. et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 306, 1786-1789 (2004).
116. Silk, J. D., Salio, M., Brown, J., Jones, E. Y. & Cerundolo, V. Structural and functional aspects of lipid binding by CD1 molecules. Annu. Rev. Cell Dev. Biol. 24, 369-395 (2008).
117. Porubsky, S. et al. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc. Natl Acad. Sci. USA 104, 5977-5982 (2007).
118. Speak, A. O. et al. Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc. Natl Acad. Sci. USA 104, 5971-5976 (2007).
119. Christiansen, D. et al. Humans lack iGb3 due to the absence of functional iGb3-synthase: implications for NKT cell development and transplantation. PLoS Biol. 6, e172 (2008).
120. Li, Y. et al. Sensitive detection of isoglobo and globo series tetraglycosylceramides in human thymus by ion trap mass spectrometry. Glycobiology 18, 158-165 (2008).
121. Gumperz, J. E. et al. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 12, 211-221 (2000).
122. Park, J. E. et al. Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand. Immunology 123, 145-155 (2008).
123. + T cells in major histocompatibility complex class II-deficient mice. J. Exp. Med. 182, 993-1004 (1995).
124. Jahng, A. et al. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J. Exp. Med. 199, 947-957 (2004).
125. Berzofsky, J. A. & Terabe, M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J. Immunol. 180, 3627-3635 (2008).
126. Stewart-Jones, G. B., McMichael, A. J., Bell, J. I., Stuart, D. I. & Jones, E. Y. A structural basis for immunodominant human T cell receptor recognition. Nature Immunol. 4, 657-663 (2003).
127. Chen, J. L. et al. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J. Exp. Med. 201, 1243-1255 (2005).